Biocon · NSE: BIOCON · BSE: 532523
Q4 FY26 results · Jan–Mar 2026
Biocon reported revenue from operations of ₹4,516.60 crore (up 2.3% from Q4 FY25) and net profit of ₹198.60 crore (down 56.8% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4,516.60 | 4,417.00 | +2.3% | 4,173.00 | +8.2% |
| Other income | 52.50 | 36.90 | +42.3% | 117.30 | −55.2% |
| Total income | 4,569.10 | 4,453.90 | +2.6% | 4,290.30 | +6.5% |
| Profit before tax | 247.50 | 486.80 | −49.2% | (67.80) | Turned profit |
| Net profit for the period | 198.60 | 459.40 | −56.8% | (51.80) | Turned profit |
| Attributable to shareholders of the company | 125.90 | 344.50 | −63.5% | 143.80 | −12.4% |
| EPS, basic (₹) | 0.79 | 2.88 | not comparable | 1.08 | not comparable |
| Net margin (%) | 4.4 | 10.4 | -1.2 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 604.70 | 643.80 | −6.1% | 621.30 | −2.7% |
| Other income | 49.80 | 62.70 | −20.6% | 74.80 | −33.4% |
| Total income | 654.50 | 706.50 | −7.4% | 696.10 | −6.0% |
| Profit before tax | 57.40 | 35.00 | +64.0% | (84.50) | Turned profit |
| Net profit for the period | 51.00 | 21.20 | +140.6% | (76.40) | Turned profit |
| EPS, basic (₹) | 0.32 | 0.18 | not comparable | (0.57) | not comparable |
| Net margin (%) | 8.4 | 3.3 | -12.3 |
Consolidated
- Filed with BSE
- 07 May 2026, 23:48 IST
- Board meeting
- 07 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 May 2026, 23:48 IST
- Board meeting
- 07 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE